表紙:世界のドライアイ市場 - 産業分析、市場規模、シェア、成長、動向、予測、(2017年~2025年)
市場調査レポート
商品コード
606145

世界のドライアイ市場 - 産業分析、市場規模、シェア、成長、動向、予測、(2017年~2025年)

Dry Eye Disease Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017 - 2025

出版日: | 発行: Transparency Market Research | ページ情報: 英文 201 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.10円
世界のドライアイ市場 - 産業分析、市場規模、シェア、成長、動向、予測、(2017年~2025年)
出版日: 2018年01月22日
発行: Transparency Market Research
ページ情報: 英文 201 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のドライアイ市場について調査し、市場の概要、製品タイプ・流通チャネル・地域別の市場動向、市場規模の推移と予測、市場成長・阻害要因ならびに市場機会の分析、市場シェア、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義と範囲
  • 市場セグメンテーション
  • 主な調査目的
  • 調査のハイライト

第2章 前提条件と調査方法

第3章 エグゼクティブサマリー

第4章 市場の概要

  • イントロダクション
  • 概要
  • 市場のダイナミクス
    • 成長要因
    • 阻害要因
    • 市場機会
  • ドライアイ市場の分析と予測
    • 収益予測
  • ファイブフォース分析
  • 市場の見通し
  • ドライアイの罹患率
  • パイプライン分析:ドライアイ治療薬
  • 自己血清点眼液 - 概要
  • 主な産業動向

第5章 世界のドライアイ市場の分析と予測:製品タイプ別

  • イントロダクション
  • 主な発展動向
  • 主要動向
  • 市場規模の予測:製品タイプ別
    • 人工涙液
    • 抗炎症薬
    • 涙点プラグ
    • 分泌促進剤
    • その他
  • 市場魅力分析:製品タイプ別

第6章 世界のドライアイ市場の分析と予測:流通チャネル別

  • イントロダクション
  • 主な発展動向
  • 主要動向
  • 市場規模の予測:流通チャネル別
    • 病院薬局
    • 小売薬局 & ドラッグストア
    • オンライン薬局
  • 市場魅力分析:流通チャネル別

第7章 世界のドライアイ市場の分析と予測:地域別

  • 主な所見
  • 市場規模の予測:地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力分析:地域別
  • 市場動向:地域別

第8章 北米

第9章 欧州

第10章 アジア太平洋

第11章 ラテンアメリカ

第12章 中東・アフリカ

第13章 競合情勢

  • 参入企業の競合分析(ティアおよび企業規模別)
  • 企業の市場シェア
  • 企業プロファイル(詳細 - 概要、財務、最新動向、戦略)
    • Santen Pharmaceutical Co., Ltd.
    • Novartis AG
    • Valeant Pharmaceuticals International, Inc.
    • Allergan plc
    • Shire plc
    • TRB Chemedica International SA
    • Sun Pharmaceutical Industries Ltd.
    • 千寿製薬
    • Sentiss Pharma Pvt. Ltd.
    • Johnson & Johnson
    • 大塚製薬
    • Mitotech SA
    • FCI SAS
図表

List of Tables

  • Table 01: Pipeline Analysis (1/5)
  • Table 02: Pipeline Analysis (2/5)
  • Table 03: Pipeline Analysis (3/5)
  • Table 04: Pipeline Analysis (4/5)
  • Table 05: Pipeline Analysis (5/5)
  • Table 06: Global Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015-2025
  • Table 07: Global Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015-2025
  • Table 08: Global Dry Eye Disease Market Size (US$ Mn) Forecast, by Distribution channel, 2015-2025
  • Table 09: Global Dry Eye Disease Market Size (US$ Mn) Forecast, by Region, 2015-2025
  • Table 10: North America Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015-2025
  • Table 11: North America Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015-2025
  • Table 12: North America Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015-2025
  • Table 13: North America Dry Eye Disease Market Value (US$ Mn) Forecast, by Country, 2015-2025
  • Table 14: Europe Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015-2025
  • Table 15: Europe Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015-2025
  • Table 16: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015-2025
  • Table 17: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015-2025
  • Table 18: Asia Pacific Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015-2025
  • Table 19: Asia Pacific Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015-2025
  • Table 20: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015-2025
  • Table 21: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015-2025
  • Table 22: Latin America Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015-2025
  • Table 23: Latin America Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015-2025
  • Table 24: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015-2025
  • Table 25: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015-2025
  • Table 26: Middle East & Africa Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015-2025
  • Table 27: Middle East & Africa Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015-2025
  • Table 28: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015-2025
  • Table 29: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015-2025

List of Figures

  • Figure 01: Dry Eye Disease Market Size (US$ Mn), by Product Type, 2016 (A)
  • Figure 02: Dry Eye Disease Market Revenue (%), by Distribution channel, 2016 (A)
  • Figure 03: Global Dry Eye Disease Market Revenue (%), by Region, 2016 (A)
  • Figure 04: Product Type Revenue (%), 2016
  • Figure 05: Distribution Channel Revenue (%), 2016
  • Figure 06: Global Dry Eye Disease Market Size (US$ Mn) Forecast, 2015-2025
  • Figure 07: Market Value Share, by Product Type (2016)
  • Figure 08: Market Value Share, by Distribution Channel (2016)
  • Figure 09: Market Value Share, by Region (2016)
  • Figure 10: Global Prevalence Dry eye Disease
  • Figure 11: Global Dry Eye Disease Market Value Share, by Product Type, 2016 and 2025
  • Figure 12: Global Dry Eye Disease Market Attractiveness, by Product Type, 2017-2025
  • Figure 13: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Artificial Tears, 2015-2025
  • Figure 14: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anti-inflammatory Drugs, 2015-2025
  • Figure 15: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Punctal Plugs, 2015-2025
  • Figure 16: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Secretagogue, 2015-2025
  • Figure 17: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015-2025
  • Figure 18: Global Dry Eye Disease Market Value Share, by Distribution channel, 2016 and 2025
  • Figure 19: Global Dry Eye Disease Market Attractiveness, by Distribution channel, 2017-2025
  • Figure 20: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015-2025
  • Figure 21: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Independent Pharmacies & Drug Stores, 2015-2025
  • Figure 22: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2015-2025
  • Figure 23: Global Market Scenario
  • Figure 24: Global Dry Eye Disease Market Value Share, by Region, 2016 and 2025
  • Figure 25: Global Dry Eye Disease Market Attractiveness, by Region, 2017-2025
  • Figure 26: North America Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2025
  • Figure 27: North America Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
  • Figure 28: North America Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
  • Figure 29: North America Dry Eye Disease Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 30: North America Dry Eye Disease Market Attractiveness Analysis, by Country
  • Figure 31: North America Dry Eye Disease Market Attractiveness Analysis, by Product Type
  • Figure 32: North America Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
  • Figure 33: Europe Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2025
  • Figure 34: Europe Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
  • Figure 35: Europe Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
  • Figure 36: Europe Dry Eye Disease Market Value Share Analysis, by Country / Sub-region, 2016 and 2025
  • Figure 37: Europe Dry Eye Disease Market Attractiveness Analysis, by Country / Sub-region
  • Figure 38: Europe Dry Eye Disease Market Attractiveness Analysis, by Product Type
  • Figure 39: Europe Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
  • Figure 40: Asia Pacific Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2025
  • Figure 41: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
  • Figure 42: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
  • Figure 43: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Country / Sub-region, 2016 and 2025
  • Figure 44: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Country / Sub-region
  • Figure 45: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Product Type
  • Figure 46: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
  • Figure 47: Latin America Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2025
  • Figure 48: Latin America Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
  • Figure 49: Latin America Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
  • Figure 50: Latin America Dry Eye Disease Market Value Share Analysis, by Country / Sub-region, 2016 and 2025
  • Figure 51: Latin America Dry Eye Disease Market Attractiveness Analysis, by Country / Sub-region
  • Figure 52: Latin America Dry Eye Disease Market Attractiveness Analysis, by Product Type
  • Figure 53: Latin America Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
  • Figure 54: Middle East & Africa Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2025
  • Figure 55: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
  • Figure 56: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
  • Figure 57: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Country / Sub-region, 2016 and 2025
  • Figure 58: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Country / Sub-region
  • Figure 59: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Product Type
  • Figure 60: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
  • Figure 61: Global Dry Eye Disease Market Share Analysis, by Company (2016)
  • Figure 62: Santen Pharmaceutical Co., Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 63: Santen Pharmaceutical Co., Ltd. R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 64: Santen Pharmaceutical Co., Ltd. Breakdown of Net Sales, By Business Segment, 2016
  • Figure 65: Novartis AG. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 66: Novartis AG. R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 67: Novartis AG. Breakdown of Net Sales, By Region, 2016
  • Figure 68: Valeant Pharmaceuticals International, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 69: Valeant Pharmaceuticals International, Inc. R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2014-2016
  • Figure 70: Valeant Pharmaceuticals International, Inc. Breakdown of Net Sales, By Business Segment, 2016
  • Figure 71: Allergan plc Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 72: Allergan plc R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 73: Allergan plc Breakdown of Net Sales, By Business Segment, 2016
  • Figure 74: Shire plc Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 75: Shire plc R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 76: Shire plc Breakdown of Net Sales, By Business Segment, 2016
  • Figure 77: Sun Pharmaceutical Industries Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 78: Sun Pharmaceutical Industries Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 79: Sun Pharmaceutical Industries Ltd. Breakdown of Net Sales, By Region, 2016
  • Figure 80: Senju Pharmaceutical Co., Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 81: Senju Pharmaceutical Co., Ltd. Breakdown of Net Sales, By Business Segment, 2016
  • Figure 82: Johnson & Johnson Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 83: Johnson & Johnson R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 84: Johnson & Johnson Breakdown of Net Sales, By Business Segment, 2016
  • Figure 85: Otsuka Pharmaceutical Co., Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 86: Otsuka Pharmaceutical Co., Ltd. R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 87: Otsuka Pharmaceutical Co., Ltd. Breakdown of Net Sales, By Business Segment, 2016
目次

Title:
Dry Eye Disease Market (Product - Artificial Tears, Anti-inflammatory (Cyclosporine, Corticosteroid, and Lifitegrast), Punctal Plugs, and Secretagogue; Distribution Channel - Hospital Pharmacies, Independent Pharmacies & Drug Stores, and Online pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017 - 2025.

Global Dry Eye Disease Market: Overview

Dry eye is an ocular disease caused due to insufficiency or lack of tears in eye. Tears made up of three layers viz. lipids, mucin and aqueous keep eye moist and lubricated. Lack of tears lead to redness, burning, sensing and pain in eye. Dry eye disease also known as Keratoconjuctivitis Sicca is a common phenomenon, which is estimated to have prevalence of 8% to 34% across the globe. Dry eye disease is categorized into evaporative dry eye disease and aqueous deficiency dry eye disease. Dry eye is a multifactorial disease, most of the currently approved prescription and currently approved dry eye treatment products are targeted to relief the signs and symptoms of dry eye disease. The choice of treatment depends upon the type and severity of dry eye disease.

Global Dry Eye Disease Market: Scope of the Study

This report on the dry eye disease market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year.

Market related factors such as technological developments, product innovation, expansion of healthcare infrastructure facilities around the world, and historical year-on-year growth have been taken into consideration while estimating the market size. Growth rates for each segment within the dry eye disease market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, product development life cycle, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the global market.

Global Dry Eye Disease Market: Key Segments

On the basis of products, the dry eye disease market is categorized into artificial tears, anti-inflammatory drugs, punctal plugs, secretagogue and others. The anti-inflammatory drugs segment is further classified into cyclosporine, corticosteroids and lifitegrast. While the others segment include oral omega supplements, oral tetracycline and eye inserts. On the basis of distribution channel, the dry eye disease market is categorized into hospital pharmacies, independent pharmacies & drug stores and online pharmacies.

Global Dry Eye Disease Market: Regional Outlook

On the basis of geography, the dry eye disease market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America comprises the U.S. and Canada. Europe comprises Germany, France, U.K., Spain, Italy and Rest of Europe. Asia-Pacific comprises China, India, Japan, Australia & New Zealand and Rest of Asia Pacific. Latin America comprises Brazil, Mexico and Rest of Latin America. Middle East & Africa comprises of GCC Countries, South Africa and Rest of Middle East & Africa.

Global Dry Eye Disease Market: Competitive Outlook

The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the dry eye disease market. The report also profiles major players in the dry eye disease market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Santen Pharmaceutical Co., Ltd., Novartis AG, Valeant Pharmaceuticals International, Inc., Allergan plc, Shire plc, TRB Chemedica International SA, Sun Pharmaceutical Industries Ltd., Senju Pharmaceutical Co., Ltd., Sentiss Pharma Pvt. Ltd., Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Mitotech S.A. and FCI S.A.S.

The global dry eye disease market has been segmented as follows:

Global Dry Eye Disease Market, by Product

  • Artificial Tears
  • Anti-inflammatory Drugs
  • Cyclosporine
  • Corticosteroids
  • Lifitegrast
  • Punctal Plugs
  • Secretagogue
  • Others

Global Dry Eye Disease Market, by Distribution Channel

  • Hospital Pharmacies
  • Independent Pharmacies & Drug Stores
  • Online Pharmacies

Global Dry Eye Disease Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of MEA

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Dye Eye Disease Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
      • 4.3.1.1. High prevalence and rise in incidence rates of dry eye disease and associated risk factors
      • 4.3.1.2. Technical advancements and promising pipeline products
      • 4.3.1.3. Novel dry eye diagnostic tools in offering
      • 4.3.1.4. Growing number of eye care centers prompting surge in product utilization
    • 4.3.2. Restraints
      • 4.3.2.1. High cost of specialty dry eye products with Unclear Reimbursement Scenario
      • 4.3.2.2. Alternative therapies in offering
    • 4.3.3. Opportunities
      • 4.3.3.1. Development of novel treatments
  • 4.4. Global Dye Eye Disease Market Analysis and Forecasts, 2015-2025
    • 4.4.1. Market Revenue Projections (US$ Mn)
  • 4.5. Porter's Five Force Analysis
  • 4.6. Market Outlook
  • 4.7.Global Prevalence of Dry Eye Disease
  • 4.8.Pipeline Analysis : Dry Eye Disease Drugs
  • 4.9.Autologous Serum Tears - Overview
  • 4.10.Key Industry Trends

5. Global Dye Eye Disease Market Analysis and Forecasts, By Product

  • 5.1. Introduction & Definition
  • 5.2. Key Findings / Developments
  • 5.3. Key Trends
  • 5.4. Market value Forecast By Product, 2015-2025
    • 5.4.1. Artificial Tears
    • 5.4.2. Anti-inflammatory
      • 5.4.2.1. Cyclosporine
      • 5.4.2.2. Corticosteroid
      • 5.4.2.3. Lifitegrast
    • 5.4.3. Punctal Plugs
    • 5.4.4. Secretagogue
    • 5.4.5. Others
  • 5.5. Market Attractiveness By Product

6. Global Dye Eye Disease Market Analysis and Forecasts, By Distribution Channel

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Key Trends
  • 6.4. Market value Forecast By Distribution Channel, 2015-2025
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Independent Pharmacies & Drug Stores
    • 6.4.3. Online Pharmacies
  • 6.5. Market Attractiveness By Distribution Channel

7. Global Dye Eye Disease Market Analysis and Forecasts, By Region

  • 7.1. Key Findings
  • 7.2. Market value Forecast By Region
    • 7.2.1. North America
    • 7.2.2. Europe
    • 7.2.3. Asia Pacific
    • 7.2.4. Latin America
    • 7.2.5. Middle East & Africa
  • 7.3. Market Attractiveness By Region
  • 7.4. Key Trends, By Region

8. North America Dye Eye Disease Market Analysis and Forecast

  • 8.1. Key Findings
  • 8.2. Market value Forecast By Product, 2015-2025
    • 8.2.1. Artificial Tears
    • 8.2.2. Anti-inflammatory
      • 8.2.2.1. Cyclosporine
      • 8.2.2.2. Corticosteroid
      • 8.2.2.3. Lifitegrast
    • 8.2.3. Punctal Plugs
    • 8.2.4. Secretagogue
    • 8.2.5. Others
  • 8.3. Market value Forecast By Distribution Channel, 2015-2025
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Independent Pharmacies & Drug Stores
    • 8.3.3. Online Pharmacies
  • 8.4. Market value Forecast By Country, 2015-2025
    • 8.4.1. US
    • 8.4.2. Canada
  • 8.5. Market Attractiveness Analysis
    • 8.5.1. By Product
    • 8.5.2. By Distribution Channel
    • 8.5.3. By Country

9. Europe Dye Eye Disease Market Analysis and Forecast

  • 9.1. Key Findings
  • 9.2. Market value Forecast By Product, 2015-2025
    • 9.2.1. Artificial Tears
    • 9.2.2. Anti-inflammatory
      • 9.2.2.1. Cyclosporine
      • 9.2.2.2. Corticosteroid
      • 9.2.2.3. Lifitegrast
    • 9.2.3. Punctal Plugs
    • 9.2.4. Secretagogue
    • 9.2.5. Others
  • 9.3. Market value Forecast By Distribution Channel, 2015-2025
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Independent Pharmacies & Drug Stores
    • 9.3.3. Online Pharmacies
  • 9.4. Market value Forecast By Country / Sub-region, 2015-2025
    • 9.4.1. Germany
    • 9.4.2. UK
    • 9.4.3. France
    • 9.4.4. Italy
    • 9.4.5. Spain
    • 9.4.6. Rest of Europe
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Product
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country / Sub-region

10. Asia Pacific Dye Eye Disease Market Analysis and Forecast

  • 10.1.Key Findings
  • 10.2.Market value Forecast By Product, 2015-2025
    • 10.2.1. Artificial Tears
    • 10.2.2. Anti-inflammatory
      • 10.2.2.1. Cyclosporine
      • 10.2.2.2. Corticosteroid
      • 10.2.2.3. Lifitegrast
    • 10.2.3. Punctal Plugs
    • 10.2.4. Secretagogue
    • 10.2.5. Others
  • 10.3.Market value Forecast By Distribution Channel, 2015-2025
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Independent Pharmacies & Drug Stores
    • 10.3.3. Online Pharmacies
  • 10.4.Market value Forecast By Country / Sub-region, 2015-2025
    • 10.4.1. China
    • 10.4.2. Japan
    • 10.4.3. India
    • 10.4.4. Australia and New Zealand
    • 10.4.5. Rest of APAC
  • 10.5.Market Attractiveness Analysis
    • 10.5.1. By Product
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country / Sub-region

11. Latin America Dye Eye Disease Market Analysis and Forecast

  • 11.1.Key Findings
  • 11.2.Market value Forecast By Product, 2015-2025
    • 11.2.1. Artificial Tears
    • 11.2.2. Anti-inflammatory
      • 11.2.2.1. Cyclosporine
      • 11.2.2.2. Corticosteroid
      • 11.2.2.3. Lifitegrast
    • 11.2.3.Punctal Plugs
    • 11.2.4. Secretagogue
    • 11.2.5. Others
  • 11.3.Market value Forecast By Distribution Channel, 2015-2025
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Independent Pharmacies & Drug Stores
    • 11.3.3. Online Pharmacies
  • 11.4.Market value Forecast By Country / Sub-region, 2015-2025
    • 11.4.1. Brazil
    • 11.4.2. Mexico
    • 11.4.3. Rest of LATAM
  • 11.5.Market Attractiveness Analysis
    • 11.5.1. By Product
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country / Sub-region

12. Middle East & Africa Dye Eye Disease Market Analysis and Forecast

  • 12.1.Key Findings
  • 12.2.Market value Forecast By Product, 2015-2025
    • 12.2.1. Artificial Tears
    • 12.2.2. Anti-inflammatory
      • 12.2.2.1. Cyclosporine
      • 12.2.2.2. Corticosteroid
      • 12.2.2.3. Lifitegrast
    • 12.2.3. Punctal Plugs
    • 12.2.4. Secretagogue
    • 12.2.5. Others
  • 12.3.Market value Forecast By Distribution Channel, 2015-2025
    • 12.3.1. Hospital Pharmacies
    • 12.3.2. Independent Pharmacies & Drug Stores
    • 12.3.3. Online Pharmacies
  • 12.4.Market value Forecast By Country / Sub-region, 2015-2025
    • 12.4.1. GCC Countries
    • 12.4.2. South Africa
    • 12.4.3. Israel
    • 12.4.4. Rest of MEA
  • 12.5.Market Attractiveness Analysis
    • 12.5.1. By Product
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country / Sub-region

13. Competition Landscape

  • 13.1.Market Player - Competition Matrix (By Tier and Size of companies)
  • 13.2.Market Share Analysis By Company (2016)
  • 13.3.Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
    • 13.3.1. Santen Pharmaceutical Co., Ltd.
      • 13.3.1.1. Company Overview
      • 13.3.1.2. Business Overview
      • 13.3.1.3. Product Overview
      • 13.3.1.4. Financial Overview
      • 13.3.1.5. Strategic Overview
      • 13.3.1.6. SWOT Analysis
    • 13.3.2. Novartis AG
      • 13.3.2.1. Company Overview
      • 13.3.2.2. Business Overview
      • 13.3.2.3. Product Overview
      • 13.3.2.4. Financial Overview
      • 13.3.2.5. Strategic Overview
      • 13.3.2.6. SWOT Analysis
    • 13.3.3. Valeant Pharmaceuticals International, Inc.
      • 13.3.3.1. Company Overview
      • 13.3.3.2. Business Overview
      • 13.3.3.3. Product Overview
      • 13.3.3.4. Financial Overview
      • 13.3.3.5. Strategic Overview
      • 13.3.3.6. SWOT Analysis
    • 13.3.4. Allergan plc
      • 13.3.4.1. Company Overview
      • 13.3.4.2. Business Overview
      • 13.3.4.3. Product Overview
      • 13.3.4.4. Financial Overview
      • 13.3.4.5. Strategic Overview
      • 13.3.4.6. SWOT Analysis
    • 13.3.5. Shire plc
      • 13.3.5.1. Company Overview
      • 13.3.5.2. Business Overview
      • 13.3.5.3. Product Overview
      • 13.3.5.4. Financial Overview
      • 13.3.5.5. Strategic Overview
      • 13.3.5.6. SWOT Analysis
    • 13.3.6. TRB Chemedica International SA
      • 13.3.6.1. Company Overview
      • 13.3.6.2. Business Overview
      • 13.3.6.3. Product Overview
      • 13.3.6.4. Strategic Overview
      • 13.3.6.5. SWOT Analysis
    • 13.3.7. Sun Pharmaceutical Industries Ltd.
      • 13.3.7.1. Company Overview
      • 13.3.7.2. Business Overview
      • 13.3.7.3. Product Overview
      • 13.3.7.4. Financial Overview
      • 13.3.7.5. Strategic Overview
      • 13.3.7.6. SWOT Analysis
    • 13.3.8. Senju Pharmaceutical Co., Ltd.
      • 13.3.8.1. Company Overview
      • 13.3.8.2. Business Overview
      • 13.3.8.3. Product Overview
      • 13.3.8.4. Financial Overview
      • 13.3.8.5. Strategic Overview
      • 13.3.8.6. SWOT Analysis
    • 13.3.9. Sentiss Pharma Pvt. Ltd.
      • 13.3.9.1. Company Overview
      • 13.3.9.2. Business Overview
      • 13.3.9.3. Product Overview
      • 13.3.9.4. Strategic Overview

\ 13.3.9.5. SWOT Analysis

    • 13.3.10. Johnson & Johnson
      • 13.3.10.1. Company Overview
      • 13.3.10.2. Business Overview
      • 13.3.10.3. Product Overview
      • 13.3.10.4. Financial Overview
      • 13.3.10.5. Strategic Overview
      • 13.3.10.6. SWOT Analysis
    • 13.3.11. Otsuka Pharmaceutical Co., Ltd.
      • 13.3.11.1. Company Overview
      • 13.3.11.2. Business Overview
      • 13.3.11.3. Product Overview
      • 13.3.11.4. Financial Overview
      • 13.3.11.5. Strategic Overview
      • 13.3.11.6. SWOT Analysis
    • 13.3.12. Mitotech S.A.
      • 13.3.12.1. Company Overview
      • 13.3.12.2. Business Overview
      • 13.3.12.3. Product Overview
      • 13.3.12.4. Strategic Overview
      • 13.3.12.5. SWOT Analysis
    • 13.3.13. FCI S.A.S.
      • 13.3.13.1. Company Overview
      • 13.3.13.2. Business Overview
      • 13.3.13.3. Product Overview
      • 13.3.13.4. Strategic Overview
      • 13.3.13.5. SWOT Analysis